TNFRSF6B and renal cell carcinoma: Treatment of RCC cell lines with both the PI3K-inhibitor LY294002 and the AKT-inhibitor IV (CAS-number: 681281-88-9) resulted in a strongly reduced DcR3 expression on both protein and mRNA level, indicating a regulation of DcR3 on the transcriptional level (Figure 4A).